Abstract: A lubricant composition comprising an oil of lubricating viscosity and 0.01 to 5 percent by weight of a substantially sulfur-free alkyl phosphate amine salt, where at least 30 mole percent of the phosphorus atoms are in an alkyl pyrophosphate salt structure, exhibits good antiwear performance. In the phosphate amine salt, at least 80 mole percent of the alkyl groups are typically secondary alkyl groups of 3 to 12 carbon atoms.

Abstract: A method of enhancing the growth of an animal is provided. The method includes causing the animal to ingest or absorb an effective amount of one or more Fe III complex compounds, including but not limited to Fe III complexes comprising ligands bound to the iron center selected from amino acids or ?-hydroxy acids, o-hydroxy benzoic acids or pyridine-2-carboxylic acids, such as ferric quinate, ferric tyrosine, ferric DOPA and ferric phenylalanine. Compounds which are structural and/or functional variants, derivatives and/or analogs of the foregoing compounds, as further described herein are also disclosed.

Abstract: The invention describes a novel dissymmetric nickel-based complex and the method of preparation thereof from at least one diphosphinamine ligand B1 of formula (R1)(R?1)P—N(R3)—P(R2)(R?2), or an iminobisphosphine ligand B2 of formula (R3)N?P(R1)(R?1)—P(R2)(R?2). The invention also concerns the use of said complex in a method for oligomerisation of olefins.

Abstract: The present invention relates to a ligand compound, a catalyst system for ethylene oligomerization, and a method for ethylene oligomerization using the same. The catalyst system for ethylene oligomerization according to the present invention not only has excellent catalytic activity but also shows more improved liquid olefin selectivity, and enables more effective preparation of an alpha-olefin through the oligomerization of ethylene because it is particularly possible to control the selectivity to 1-hexene or 1-octene.

Abstract: An efficient process for synthesizing phosphaplatins in large quantities is disclosed by adding platinum complex to a concentrated pyrophosphate solution at pH from between about 6.0 to 8.5. After stirring, the temperature and pH are lowered to precipitate out desired phosphaplatins. Particularly, the disclosed processes reduce the need to use large volumes of starting materials, and shorten the reaction time. In addition, disclosed is a process for recycling un-reacted materials from a first phosphaplatins synthesis.

Abstract: This application discloses novel methods and processes for preparation and purification of phosphaplatin compounds. The improvements of the synthetic methods and purification processes include, but are not limited to, efficient and reproducible large-scale preparation of these useful pharmaceutical agents in high quality and good yield.

Abstract: This application discloses novel methods and processes for preparation and purification of phosphaplatin compounds. The improvements of the synthetic methods and purification processes include, but are not limited to, efficient and reproducible large-scale preparation of these useful pharmaceutical agents in high quality and good yield.

Abstract: This application discloses novel methods and processes for preparation and purification of phosphaplatin compounds. The improvements of the synthetic methods and purification processes include, but are not limited to, efficient and reproducible large-scale preparation of these useful pharmaceutical agents in high quality and good yield.

Abstract: The complex of the present invention containing an onium salt and a central Lewis acidic metal has a high catalytic activity at a high temperature for the copolymerization of an epoxide and carbon dioxide to produce a high molecular weight polycarbonate.

Abstract: The complex of the present invention containing an onium salt and a central Lewis acidic metal has a high catalytic activity at a high temperature for the copolymerization of an epoxide and carbon dioxide to produce a high molecular weight polycarbonate.

Abstract: The present disclosure provides for compositions for the treatment of neurodegenerative diseases comprising one or more isolated phosphate complexes of platinum and methods of uses thereof for treating neurodegenerative diseases including amyotrophic lateral sclerosis, Alzheimer's disease, stroke, epilepsy, Parkinsons, Huntington's disease and diabetes associated peripheral neuropathy The present disclosure is also directed towards an anti-angiogenic composition useful for inhibiting angiogenesis related to age-related macular degeneration, diabetic retinopathy and tumor-associated angiogenesis. An embodiment of the present disclosure is also directed towards a method for modulating the expression of Pigment Epithelial Derived Factor (PEDF) gene in an individual in need thereof.

Abstract: A composition contains (A) a hydrosilylation reaction catalyst and (B) an aliphatically unsaturated compound having an average, per molecule, of one or more aliphatically unsaturated organic groups capable of undergoing hydrosilylation reaction. The composition is capable of reacting via hydrosilylation reaction to form a reaction product, such as a silane, a gum, a gel, a rubber, or a resin. Ingredient (A) contains a metal-ligand complex that can be prepared by a method including reacting a metal precursor and a ligand.

Abstract: The present invention provides pharmaceutical compositions comprising phosphaplatins, stable isolated monomeric phosphato complexes of platinum (II) and (IV). In some embodiments, such compositions may be useful for treating cancers, including cisplatin- and carboplatin-resistant cancers. The provided phosphaplatin complexes do not readily undergo hydrolysis and are quite soluble and stable in aqueous solutions. Moreover, these complexes—unlike cisplatin, carboplatin, and related platinum-based agents—do not bind DNA. Rather, data suggests that phosphaplatins trigger overexpression of fas and fas-related transcription factors and some proapoptotic genes such as Bak and Bax. Nevertheless, the complexes exhibit tremendous cytotoxicity towards cancer cells. Thus, the present invention provides novel platinum agents that have a different molecular target than those in the art.

Abstract: This application discloses novel methods and processes for preparation and purification of phosphaplatin compounds. The improvements of the synthetic methods and purification processes include, but are not limited to, efficient and reproducible large-scale preparation of these useful pharmaceutical agents in high quality and good yield.

Abstract: The present invention provides pharmaceutical compositions comprising phosphaplatins, stable isolated monomeric phosphato complexes of platinum (II) and (IV). In some embodiments, such compositions may be useful for treating cancers, including cisplatin- and carboplatin-resistant cancers. The provided phosphaplatin complexes do not readily undergo hydrolysis and are quite soluble and stable in aqueous solutions. Moreover, these complexes—unlike cisplatin, carboplatin, and related platinum-based agents—do not bind DNA. Rather, data suggests that phosphaplatins trigger overexpression of fas and fas-related transcription factors and some proapoptotic genes such as Bak and Bax. Nevertheless, the complexes exhibit tremendous cytotoxicity towards cancer cells. Thus, the present invention provides novel platinum agents that have a different molecular target than those in the art.

Abstract: An efficient process for synthesizing phosphaplatins in large quantities is disclosed by adding platinum complex to a concentrated pyrophosphate solution at pH from between about 6.0 to 8.5. After stirring, the temperature and pH are lowered to precipitate out desired phosphaplatins. Particularly, the disclosed processes reduce the need to use large volumes of starting materials, and shorten the reaction time. In addition, disclosed is a process for recycling un-reacted materials from a first phosphaplatins synthesis.

Abstract: The present invention provides phosphaplatins, stable isolated monomeric phosphato complexes of platinum (II) and (IV), and methods of use thereof for treating cancers, including cisplatin- and carboplatin-resistant cancers. Unlike cisplatin, these complexes do not readily undergo hydrolysis and are quite soluble and stable in aqueous solutions. Moreover, these complexes—unlike cisplatin, carboplatin, and related platinum-based anti-cancer agents—do not bind DNA. Rather, data suggests that phosphaplatins trigger overexpression of fas and fas-related transcription factors and some proapoptotic genes such as Bak and Bax. Nevertheless, the complexes exhibit tremendous cytotoxicity towards cancer cells. Thus, the present invention provides novel platinum anticancer agents that have a different molecular target than those in the art.

Abstract: Stable monomeric phosphaplatins, namely, (pyrophosphato)platinum(II) or platinum(IV) complexes containing a cis-cyclohexanediamine ligand or enantiomerically enriched or enantiopure trans-cyclohexanediamine ligands, and synthesis of these complexes, are provided. Efficacies and toxicities of the phosphaplatin compounds are determined toward a variety of cancers, including sensitive and resistant ovarian cancers, head and neck, and colon cancers. Compositions comprising the platinum complexes, and methods for treatment of proliferative diseases or disorders by means of the complexes or the compositions comprising them are disclosed.

Abstract: The complex of the present invention containing an onium salt and a central Lewis acidic metal has a high catalytic activity at a high temperature for the copolymerization of an epoxide and carbon dioxide to produce a high molecular weight polycarbonate.

Abstract: New iron preparations comprising stable, unpolymerized iron(III) citrate complex compositions and methods for their preparation are provided. Further, the invention involves the use stable, unpolymerized iron(III) citrate complex compositions of the invention as a food additive, nutritional supplement, dietary supplement, medical food, nutrient, iron fortificant, and source of iron in the fields of nutrition for humans, animals, fish, and birds and of diagnostics. The invention further involves the use of stable, unpolymerized iron(III) citrate complex compositions of the invention as a pharmaceutical and pharmacologically active ingredient for human clinical and veterinary applications.

Abstract: The present invention provides phosphaplatins, stable isolated monomeric phosphato complexes of platinum (II) and (IV), and methods of use thereof for treating cancers, including cisplatin- and carboplatin-resistant cancers. Unlike cisplatin, these complexes do not readily undergo hydrolysis and are quite soluble and stable in aqueous solutions. Moreover, these complexes—unlike cisplatin, carboplatin, and related platinum-based anti-cancer agents—do not bind DNA. Rather, data suggests that phosphaplatins trigger overexpression of fas and fas-related transcription factors and some proapoptotic genes such as Bak and Bax. Nevertheless, the complexes exhibit tremendous cytotoxicity towards cancer cells. Thus, the present invention provides novel platinum anticancer agents that have a different molecular target than those in the art.

Abstract: The present invention provides an anti-wear compound selected from phosphorus compounds as represented by the following General Formula (2) or metal salts thereof as represented by the following General Formula (3).

Abstract: The present invention provides phosphaplatins, stable isolated monomeric phosphato complexes of platinum (II) and (IV), and methods of use thereof for treating cancers, including cisplatin- and carboplatin-resistant cancers. Unlike cisplatin, these complexes do not readily undergo hydrolysis and are quite soluble and stable in aqueous solutions. Moreover, these complexes—unlike cisplatin, carboplatin, and related platinum-based anti-cancer agents—do not bind DNA. Rather, data suggests that phosphaplatins trigger overexpression of fas and fas-related transcription factors and some proapoptotic genes such as Bak and Bax. Nevertheless, the complexes exhibit tremendous cytotoxicity towards cancer cells. Thus, the present invention provides novel platinum anticancer agents that have a different molecular target than those in the art.

Abstract: Disclosed are a novel cyclotriphosphazene-platinum(II) complex conjugate anticancer agent, showing high selectivity to tumor tissues due to the enhanced permeability and retention effect in tumor tissues and a preparation method thereof.

Abstract: The present invention involves pyrophosphate bridged coordination complexes and the treatment of medical conditions, such as cancer, using the pyrophosphate bridged coordination complexes. The pyrophosphate bridged coordination complexes include four new compounds, [Co(phen)2(H2P2O7)].4H2O (1.4H2O), [Ni(phen)2(H2P2O7)].8H2O (2.8H2O), [Cu(phen)(H2O)(H2P2O7)], and {[Cn(phen)(H2O)(P2O7)] [Na2(H2O)8]}.6H2O(4.14H2O) found effective for treating cancer cells. The pyrophosphate bridged coordination complexes also include three previously reported compounds, {[Ni(phen)2]2(?-P2O7)}.27H2O (compound 11), {[Cu(phen)(H2O)]2(?-P2O7)}.8H2O (compound 12), and {[Co(phen)2]2(?-25 P2O7)}.6MeOH (compound 13), (where phen is 1,1 0?-phenanthroline), whose effectiveness in treating cancer cells was previously unknown.

Abstract: The present invention provides phosphaplatins, stable isolated monomeric phosphato complexes of platinum (II) and (IV), and methods of use thereof for treating cancers, including cisplatin- and carboplatin-resistant cancers. Unlike cisplatin, these complexes do not readily undergo hydrolysis and are quite soluble and stable in aqueous solutions. Moreover, these complexes—unlike cisplatin, carboplatin, and related platinum-based anti-cancer agents—do not bind DNA. Rather, data suggests that phosphaplatins trigger overexpression of fas and fas-related transcription factors and some proapoptotic genes such as Bak and Bax. Nevertheless, the complexes exhibit tremendous cytotoxicity towards cancer cells. Thus, the present invention provides novel platinum anticancer agents that have a different molecular target than those in the art.

Abstract: The present invention provides phosphaplatins, stable isolated monomeric phosphate complexes of platinum (II) and (IV), and methods of use thereof for treating cancers, including cisplatin- and carboplatin-resistant cancers. Unlike cisplatin, these complexes do not readily undergo hydrolysis and are quite soluble and stable in aqueous solutions. Moreover, these complexes—unlike cisplatin, carboplatin, and related platinum-based anti-cancer agents—do not bind DNA. Rather, data suggests that phosphaplatins trigger overexpression of fas and fas-related transcription factors and some proapoptotic genes such as Bak and Bax. Nevertheless, the complexes exhibit tremendous cytotoxicity towards cancer cells. Thus, the present invention provides novel platinum anticancer agents that have a different molecular target than those in the art.

Abstract: The present invention provides phosphaplatins, stable isolated monomeric phosphate complexes of platinum (II) and (IV), and methods of use thereof for treating cancers, including cisplatin- and carboplatin-resistant cancers. Unlike cisplatin, these complexes do not readily undergo hydrolysis and are quite soluble and stable in aqueous solutions. Moreover, these complexes-unlike cisplatin, carboplatin, and related platinum-based anti-cancer agents-do not bind DNA. Rather, data suggests that phosphaplatins trigger overexpression of fas and fas-related transcription factors and some proapoptotic genes such as Bak and Bax. Nevertheless, the complexes exhibit tremendous cytotoxicity towards cancer cells. Thus, the present invention provides novel platinum anticancer agents that have a different molecular target than those in the art.

Abstract: A process for the racemoselective preparation of ansa-metallocene complexes of the formula (I), where R1, R1?, R2, R2? are identical or different and are each hydrogen or an organic radical having from 1 to 40 carbon atoms, R3, R3? are identical or different and are each an organic radical having from 1 to 40 carbon atoms, T, T? are identical or different and are each a divalent organic group which has from 1 to 40 carbon atoms, A is a divalent atom or a divalent group, Z is a divalent atom or a divalent group, E is P, As or Sb, M1 is an element of group 4 of the Periodic Table of the Elements, M2 is an alkali metal, an alkaline earth metal or a magnesium monohalide fragment, p is 1 or 2.

Abstract: A metal complex comprising a metal compound complexed to a heteroatomic ligand, the metal complex having Structure X: wherein R1, R2, R3, and R4 are each independently an alkyl group, a cycloalkyl group, a substituted cycloalkyl group, an aromatic group, or a substituted aromatic group, R1c, R2c, R3c, R4c, and R5c are each independently hydrogen or an alkyl group, and MXp comprises a group IVB, VB, or VIB metal. A metal complex comprising a metal compound complexed to a diphosphino aminyl ligand comprising at least two diphosphino aminyl moieties and a linking group linking each aminyl nitrogen atom of the diphosphino aminyl moieties.

Abstract: Bisphosphonate compounds are disclosed, particularly bisphosonate conjugates useful in the treatment of soft tissues surrounding bone and bone-related diseases, such as bone cancer and osteoporosis.

Abstract: A metal complex comprising a metal compound complexed to a heteroatomic ligand, the metal complex having Structure X: wherein R1, R2, R3, and R4 are each independently an alkyl group, a cycloalkyl group, a substituted cycloalkyl group, an aromatic group, or a substituted aromatic group, R1c, R2c, R3c, R4c, and R5c are each independently hydrogen or an alkyl group, and MXp comprises a group IVB, VB, or VIB metal. A metal complex comprising a metal compound complexed to a diphosphino aminyl ligand comprising at least two diphosphino aminyl moieties and a linking group linking each aminyl nitrogen atom of the diphosphino aminyl moieties.

Abstract: A novel coordination complex formed by dinuclear metal complexation is provided. The complex is a dinuclear metal complex of a compound, wherein the compound comprises a conjugation ring system substituted with: a) an electron donating group selected from —OH, —SH and —NH2; b) an indicating group selected from a chromogenic group, a fluorescent group and an electrochemical group; and c) two binding auxiliary groups, in combination with the electron donating group each of which being coordinated with the metal to provide an anion bonding site, wherein as the complex binds to a anion, the coordination of the electron donating group with the metal is weakened and electron donation of the electron donating group to the conjugation ring system is reinforced such that the reinforced electron donation by the electron donating group is transferred through the conjugation ring system to the indicating group to produce an indicating signal concomitant with the change of its electronic density.

Abstract: Chiral ligands and metal complexes based on such chiral ligands useful in asymmetric catalysis are disclosed. The metal complexes according to the present invention are useful as catalysts in asymmetric reactions, such as, hydrogenation, hydride transfer, allylic alkylation, hydrosilylation, hydroboration, hydrovinylation, hydroformylation, olefin metathesis, hydrocarboxylation, isomerization, cyclopropanation, Diels-Alder reaction, Heck reaction, isomerization, Aldol reaction, Michael addition; epoxidation, kinetic resolution and [m+n] cycloaddition. Processes for the preparation of the ligands are also described.

Abstract: Disclosed are a new class of a polyphosphazene-platinum(II) conjugate antitumor agent having high tumor tissue selectivity due to its enhanced permeability and retention effect to tumor tissues, and a preparation method thereof: wherein x represents the number of the ethylene oxide repeating unit and is 7, 12 or 16; y is 0, 1 or 2; z represents molar content of polyethylene glycol in the range of 0.5-1.5; n represents degree of polymerization of polyphosphazene in the range of 30-100; and A-A represents a diamine.

Abstract: Disclosed are ruthenium complexes of phosphine-aminophosphine ligands that may be used to catalyze large number of reactions of a wide variety of substrates such as asymmetric hydrogenations, asymmetric reductions, asymmetric hydroborations, asymmetric olefin isomerizations, asymmetric hydrosilations, asymmetric allylations, and asymmetric organometallic additions. Also disclosed is a process for the preparation of the ruthenium complexes and processes for the enantioselective asymmetric hydrogenations of 1,3-dicarbonyl, ?-hydroxycarbonyl, and ?-hydroxycarbonyl compounds to produce the corresponding hydroxycarbonyl, 1,2-diol, and 1,3-diol compounds, respectively, using the ruthenium complexes to catalyze the hydrogenation.

Abstract: Lubricants are taught that can quickly and easily form a lubricating layer on a metal surface of a metal before plastic processing. Such lubricants preferably include a primary lubricating agent or component having a bridge complex that satisfies the following conditions: (1) the complex contains at least two central metal atoms; (2) at least one first multidentate ligand forms a bridge between two central metal atoms; and (3) at least one second multidentate ligand is bound to at least one central metal atom and has at least one coordinating atom that can coordinate with metal atoms, but which is not coordinated with any of the central metal atoms or is only partially coordinated with at least one of those central metal atoms. A third multidentate ligand is preferably also bound to one of the central metal atoms and may preferably include at least two sulfur atoms that are coordinated to the central metal atom.

Abstract: Enclosed are high refractive index and low birefringence organic/inorganic hybrid materials useful for optical applications. They are prepared from solventless metal aliphatic acryl alkoxides. The metal acryl alkoxides are synthesized from exchanging acryl alcohol with metal alkoxides, and are hydrolyzed into metal oxide nanoparticles and are well dispersed in the acrylate matrix. Then they are polymerized into organic/inorganic hybrid materials containing metal oxide in polyacrylate.

Abstract: The invention relates to surface-modified phosphinic salts of the formula (I) and/or diphosphinic salts of the formula (II) and/or polymers of these, 1

Abstract: A molybdated dispersant composition represented by the formula: (R1—NR2R3H+)m−nXn(MoHPA)m− provides good friction properties to lubricants. In the formula, R1—NR2R3 represents an amine-containing dispersant, R1 is a group providing dispersant properties to said dispersant composition, each of R2 and R3 is independently hydrogen, a hydrocarbyl group, or an additional R1 group; X is hydrogen, a monovalent metal ion, a single valence of a polyvalent metal ion, an ammonium ion, or an amine cation, m is 3 or 4, n is 0 to about 2.5 when m is 3 and 0 to about 3.5 when m is 4, and (MoHPA)m− is a molybdenum heteropolyacid anion of charge m.

Abstract: The present invention provides a novel thermosensitive cyclotriphosphazene-platinum complex conjugates represented by Formula 1, wherein m is a repeating unit of poly(alkoxyethylene glycol) selected from the integers 2, 7 and 12; n represents the length of the alkyl chain selected from the integers 0, 1, 2 and 3; x represents the length of the anionic amino acid residue selected from the integers 0 (amino malonic acid derivatives), 1 (aspartic acid derivatives) and 2 (glutamic acid derivatives); A2 is a bidentate chelating diamine selected from the group consisting of 2,2-dimethyl-1,3-propanediamine (dmpda), trans(±)-1,2-diaminocyclohexane (dach) and 1,1-diaminomethylcyclohexane (dmach).

Abstract: A compound useful as a catalyst or as a cocatalyst in combination with a Group 3-10 metal for addition polymerizations corresponding to the formula: [M′Q12L′I′]+(Arf3MQ2)— wherein: M′ is aluminum, gallium, or indium.

Abstract: The subject of the invention is to provide a new high-performance flame retardant having excellent flame resistant effect and smoke-suppressing effect and generating no hazardous gas, and a new flame retardant resin-composition used it. As a means for solution, a flame retardant comprising ethylenediamine-containing zinc phosphate and other phosphorus-containing compound is formulated in amounts of 10 to 200 parts by weight to 100 parts by weight of resin.

Abstract: Catalyst systems which comprise a transition metal and a pyrophosphite ligand are particularly effective as catalysts for hydrosilation reactions. The transition metal is from groups 7-11 of the Periodic Table, and the pyrophosphite has the following formula: ##STR1## wherein E and E' are independently a direct bond, --S--, --Se--, or --CR.sub.9 R.sub.10 -- where R.sub.9 and R.sub.10 are independently hydrogen or alkyl of 1-18 carbon atoms, and R.sub.10 can also be phenyl. R is H or methyl, R.sub.1-8 are independently H, C.sub.1-18 alkyl, C.sub.5-12 cycloalkyl, or C.sub.7-15 phenylalkyl.

Abstract: A process for extracting metal values, especially zinc values, from aqueous solutions of metal salts, which comprises contacting the aqueous solution with an organic phase comprising a compound of the formula, ##STR1## wherein each of R.sup.1, R.sup.2, R.sup.3 and R.sup.4, independently, represents an optionally substituted hydrocarbyl or hydrocarbyloxy group or R.sup.1 and R.sup.2 together with the attached phosphorus atom and/or R.sup.3 and R.sup.4 together with the attached phosphorus atom from a 5- to 8-membered heterocyclic ring.

Abstract: The invention relates to palladium compounds containing as ligands compounds of the formula (I) ##STR1## where Ar is C.sub.6 H.sub.4 SO.sub.3 M, M is hydrogen, ammonium, a monovalent metal or one equivalent of a polyvalent metal and Ph is the phenyl radical and n, m are zero, 1 or 2 and x, y, u, v are zero, 1 or 2.

Abstract: A new class of vanadium phosphate materials using a mixed valence pentavanadate as the building block has been created using hydrothermal self-assembly techniques. These materials use a framework composed solely of V.sub.5 O.sub.9 (PO.sub.4).sub.4/2 pentamers and apart from the cationic template contain some of the largest voids and cavities yet reported in open framework solids.

Abstract: Group 4 metal complexes useful as addition polymerization catalysts are prepared by electrolysis of cyclopentadienyl metal complexes under inert electrolysis conditions.

Abstract: Disclosed are bis-phosphine compounds having the general formula ##STR1## wherein: each of A.sup.1, A.sup.2, A.sup.3 and A.sup.4 is an arylene radical wherein (i) each phosphorus atom P is bonded to a ring carbon atom of A.sup.1 and A.sup.2 and to a ring carbon atom of A.sup.3 and A.sup.4, (ii) A.sup.1 and A.sup.2, and A.sup.3 and A.sup.4 are bonded to each other by ring carbon atoms and (iii) each of the residues ##STR2## constitutes a 5-membered ring; each of A.sup.5 and A.sup.6 is an arylene radical wherein A.sup.5 and A.sup.6 are bonded to each other and to residues R.sup.1 --C--R.sup.2 and R.sup.3 --C--R.sup.4 by ring carbon atoms and R.sup.1 --C--R.sup.2 and R.sup.3 --C--R.sup.4 are connected to each other through a chain of 4 carbon atoms; andR.sup.1, R.sup.2, R.sup.3 and R.sup.4 each represents hydrogen or a hydrocarbyl radical containing up to about 8 carbon atoms.

Abstract: A new class of vanadium phosphate materials has been created using hydrothermanl self-assembly techniques. Of particular interest is that these materials comprise a vanadium phosphate framework structure about an organic template that after removal leave a microporous structure. These materials typically are produced by a reaction in an aqueous solution that includes one or more phosphate sources, one or more vanadium or vanadium oxide sources, an alkali metal or alkali-earth metal sources, and an organic amine or diamine templating agent.